Novavax (NVAX) Capital Expenditures Growth (3y) (2013 - 2026)
Novavax (NVAX) Capital Expenditures Growth (3y) (2013 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Capex Growth (3y) (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
- |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
- |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
- |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
- |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
46.88% |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
- |
| 10 |
Novavax |
1.49 Bn |
931.98 Mn |
108.82 Mn |
-59.97% |
| Date | Value |
|---|
| Mar 31, 2026 |
-59.97% |
| Dec 31, 2025 |
-26.40% |
| Sep 30, 2025 |
54.60% |
| Jun 30, 2025 |
-28.47% |
| Mar 31, 2025 |
-54.40% |
| Dec 31, 2024 |
-73.21% |
| Sep 30, 2024 |
43.45% |
| Jun 30, 2024 |
-31.61% |
| Mar 31, 2024 |
-20.68% |
| Dec 31, 2023 |
40.73% |
| Sep 30, 2023 |
-34.36% |
| Jun 30, 2023 |
-91.54% |
| Mar 31, 2023 |
441.08% |
| Dec 31, 2022 |
289.64% |
| Sep 30, 2022 |
-236.54% |
| Jun 30, 2022 |
30.75% |
| Mar 31, 2022 |
175.46% |
| Dec 31, 2021 |
96.57% |
| Sep 30, 2021 |
-580.66% |
| Jun 30, 2021 |
-531.18% |
